Journal of Clinical Oncology, Vol 15, 2622-2630, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group

AG Shankar, S Ashley, M Radford, A Barrett, D Wright and CR Pinkerton
Paediatric Department, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

PURPOSE: Histology has been identified as an important prognostic factor in Hodgkin's disease (HD) in adults. Information regarding the impact of histology on outcome in childhood HD is scarce. This study determines the effect of histology on the overall survival (OS) or progression-free survival (PFS) in a national series of children treated in a standardized manner. PATIENTS AND METHODS: The results of treatment of 331 assessable patients, treated between January 1, 1982 and June 30, 1992, in the United Kingdom Children's Cancer Study Group (UKCCSG) Hodgkin's study I were reviewed to evaluate OS, PFS, and deaths according to stage and histology. Treatment was either involved- field radiation alone (stage IA) or chlorambucil, vinblastine, procarbazine, and prednisolone (ChlVPP) chemotherapy with or without mediastinal radiation. All were clinically staged at diagnosis. RESULTS: Nodular sclerosing (NS) HD was the most common histologic subtype (155 of 331 patients [47%]) and was uniformly distributed through all stages. Lymphocyte-depletion (LD) HD was extremely uncommon (< 1%). Mixed-cellularity (MC) HD had the highest relapse rate, but this was only significant (P < .05) in stage I patients who received local irradiation alone. There was no other statistically significant difference in OS and PFS between the various histologic subtypes. Multivariate analysis for PFS and OS confirmed that stage was the most important prognostic factor and that histology did not have an effect after stratification by stage. CONCLUSION: This study demonstrates that with effective multiagent chemotherapy, histologic subtype does not influence outcome. The high relapse rates in stage I MC subtype indicates that MC HD is biologically aggressive and systemic treatment with or without local irradiation may be indicated. The high relapse rate in stage IV patients appeared to be independent of histology.

This article has been cited by other articles:

				M. Alebouyeh, F. Moussavi, H. Haddad-Deylami, and P. Vossough Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results Ann. Onc., December 1, 2005; 16(12): 1936 - 1940. [Abstract] [Full Text] [PDF]

				M. M. Hudson, M. Krasin, M. P. Link, S. S. Donaldson, C. Billups, T. E. Merchant, L. Kun, A. L. Billet, S. Kaste, N. J. Tarbell, et al. Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease J. Clin. Oncol., November 15, 2004; 22(22): 4541 - 4550. [Abstract] [Full Text] [PDF]

				O. Oberlin When Quality of Life Is the Major Challenge J. Clin. Oncol., July 15, 2002; 20(14): 3051 - 3053. [Full Text] [PDF]